Zhao Qian, Wang Wen-Jia, Zhou Shui-Ping, Su Jing, Sun He, Zhai Jing-Bo, Hu Yun-Hui
Cloudphar Pharmaceuticals Co, Ltd., Shenzhen, China.
The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co, Ltd., Tianjin, China.
Front Pharmacol. 2022 Sep 26;13:959184. doi: 10.3389/fphar.2022.959184. eCollection 2022.
() infection is one of the most common chronic bacterial infections worldwide. The resistance of to antibiotics may increase the risk of treatment failure. Complementary and alternative regimens are still needed. This study aimed to critically assess the efficacy and safety of Jinghua Weikang capsule (JWC) for eradication. PubMed, Embase, Web of Science, Cochrane library, China National Knowledge Infrastructure, Wanfang Digital Periodicals, and Chinese Science and Technology Periodicals database were searched from inception to April 2022. Randomized controlled trials (RCTs) comparing a combination of JWC and conventional treatments with conventional treatments alone or combined with a placebo for eradication were considered for inclusion. The primary outcome was eradication rate. The meta-analysis and trial sequential analysis (TSA) were conducted where possible. A total of 34 studies were included in the statistical analysis. A pooled result showed that JWC with the duration of 2 weeks combined with the triple/quadruple therapy could significantly increase the eradication rate compared with the triple/quadruple therapy alone (RR: 1.13, 95% CI: 1.05 to 1.21, = 0.0008). However, the evidence of benefit was not confirmed by TSA. Another pooled result showed that JWC with the duration of 4 weeks combined with the triple/quadruple therapy could significantly increase the eradication rate compared with the triple/quadruple therapy alone (RR: 1.21, 95% CI: 1.15 to 1.27, < 0.00001). The evidence of benefit was confirmed by TSA. There were no statistically significant differences in the incidence of adverse reactions between the two groups. The present study suggests that JWC with the duration of 4 weeks can significantly improve the eradication rate and should be considered as a complementary treatment to conventional regimens for eradication. However, more high-quality RCTs are still needed to confirm these findings.
（）感染是全球最常见的慢性细菌感染之一。对该菌的抗生素耐药性可能会增加治疗失败的风险。仍需要补充和替代治疗方案。本研究旨在严格评估荆花胃康胶囊（JWC）根除该菌的疗效和安全性。检索了PubMed、Embase、Web of Science、Cochrane图书馆、中国知网、万方数据期刊和中国科技期刊数据库，检索时间从建库至2022年4月。纳入比较JWC与传统治疗联合使用、单独使用传统治疗或联合安慰剂用于根除该菌的随机对照试验（RCT）。主要结局是根除率。尽可能进行荟萃分析和试验序贯分析（TSA）。共有34项研究纳入统计分析。汇总结果显示，与单独使用三联/四联疗法相比，为期2周的JWC联合三联/四联疗法可显著提高该菌的根除率（RR：1.13，95%CI：1.05至1.21，P = 0.0008）。然而，TSA未证实获益证据。另一个汇总结果显示，与单独使用三联/四联疗法相比，为期4周的JWC联合三联/四联疗法可显著提高该菌的根除率（RR：1.21，95%CI：1.15至1.27，P < 0.00001）。TSA证实了获益证据。两组间不良反应发生率无统计学显著差异。本研究表明，为期4周的JWC可显著提高该菌的根除率，应被视为根除该菌传统治疗方案的补充治疗。然而，仍需要更多高质量的RCT来证实这些发现。
